Astragaloside IV

Saponin from astragalus inducing apoptosis, inhibiting metastasis/NF-κB; chemo-sensitizing in preclinical cancer models.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Moderate — Robust preclinical data; human trials lacking for purified compound.AS-IVAstragalosideIV

Forms: Purified astragaloside IV capsules/tablets (standardized) · Astragalus root extract enriched in AS-IV · Injection (TCM preparation, clinical use)

Educational only, not medical advice. OncoForge makes no claim that Astragaloside IV treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Astragaloside IV is a compound from the astragalus plant that triggers cancer cell death and may prevent tumor spread in lab studies. It could make chemotherapy more effective against lung and colon cancers.

Evidence at a glance

Tier 2 · animalNon-small cell lung cancerColorectal cancerBreast cancerGastric cancer

Strong preclinical anticancer activity across multiple models; chemosensitization signals; human data limited to astragalus extracts.

How it may work

Astragaloside IV (AS-IV), a saponin from Astragalus membranaceus, induces apoptosis in cancer cells through mitochondrial disruption, ROS generation, and caspase activation. It inhibits NF-κB signaling to reduce inflammation and angiogenesis, modulates macrophage polarization to curb metastasis, and enhances chemosensitivity by overcoming drug resistance. Preclinical studies demonstrate anti-proliferative effects in lung, colorectal, breast, and other cancers.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Apoptosis (cancer cells)↑Caspase activation; Bcl-2 downregulation
NF-κB↓Inhibits inflammation and survival signaling
Metastasis↓Reduces invasion/migration via macrophage modulation
Chemosensitivity↑Synergy with cisplatin, paclitaxel, gefitinib
Tumor proliferation↓Cell cycle arrest (preclinical)
Immune↑Enhances T-cell function; anti-inflammatory

Apoptosis InductionAnti-metastatic

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Chemotherapy (cisplatin, paclitaxel): Enhances sensitivity and apoptosis in preclinical studies.
Gefitinib: Sensitizes NSCLC cells via SIRT6 regulation.

Overlapping mechanisms

Apoptosis ↑, NF-κB ↓: Complements other NF-κB inhibitors; monitor for additive effects.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Immunostimulant Autoimmune CautionHypoglycemia Risk MildPregnancy AvoidInjection RiskDiarrhea Risk

Potential interactions

immunosuppressantsMonitorModerateTheoreticalImmune-boosting may counteract effects.
chemotherapy (platinum agents)MonitorTheoreticalPreclinical synergy with cisplatin; potential enhanced toxicity/efficacy.
antidiabeticsDose AdjustMildTheoreticalAdditive hypoglycemic effects.

Timing

With-meal: Improves absorption and GI tolerance.
AM
PM

References

Research

No published studies for Astragaloside IV yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Astragaloside IV depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 5–10 mg (oral) 5-10 mg/day; divided doses with meals, Standard supplement dose 5-10 mg/day; preclinical human-equivalent from 2.5-20 mg/kg in mice. TCM astragalus injections contain ~0.08 mg/mL AS-IV; consult for oncology use..

Trials studying Astragaloside IV

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar